<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00854152</url>
  </required_header>
  <id_info>
    <org_study_id>PIM4604g</org_study_id>
    <secondary_id>MP00880</secondary_id>
    <nct_id>NCT00854152</nct_id>
  </id_info>
  <brief_title>A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors and Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and&#xD;
      pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with&#xD;
      incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or&#xD;
      failed to respond to at least one prior regimen or for which there is no standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of dose-limiting toxicities</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters after doses of GDC-0980</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of GDC-0980</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response, duration of objective response, and progression-free survival for patients with measurable disease</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Non-Hodgkin's Lymphoma, Solid Cancers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Escalating repeating dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented, incurable, locally advanced or metastatic solid&#xD;
             malignancies, or NHL without leukemic phase, that has progressed despite standard of&#xD;
             care therapy or for which there is no standard therapy of proven clinical benefit&#xD;
&#xD;
          -  ECOG performance status of 0 or 1 at screening&#xD;
&#xD;
          -  Evaluable or measurable disease per RECIST and/or the following: prostate cancer&#xD;
             patients with non-measurable disease are eligible if they have two rising&#xD;
             prostate-specific antigen (PSA) levels that meet the PSA Working Group criteria for&#xD;
             progression prior to initiation of study treatment; ovarian cancer patients with&#xD;
             non-measurable disease are eligible if they have two rising CA-125 levels greater than&#xD;
             the ULN &gt;= 2 weeks apart prior to initiation of study treatment.&#xD;
&#xD;
          -  Life expectancy &gt;=12 weeks&#xD;
&#xD;
          -  Adequate hematologic and organ function within 14 days before initiation of GDC-0980&#xD;
&#xD;
          -  Documented willingness to use an effective means of contraception for both men and&#xD;
             women while participating in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Leptomeningeal disease as the only manifestation of the current malignancy&#xD;
&#xD;
          -  History of Type 1 or 2 diabetes mellitus requiring regular medication&#xD;
&#xD;
          -  Grade &gt;= 2 hypercholesterolemia or hypertriglyceridemia&#xD;
&#xD;
          -  Ejection fraction that is &lt;50% or below the LLN (whichever is higher), as determined&#xD;
             by echocardiogram or MUGA scan&#xD;
&#xD;
          -  DLCO &lt; 50% of predicted value corrected for hemoglobin and alveolar volume prior to&#xD;
             initiation of GDC-0980&#xD;
&#xD;
          -  Malabsorption syndrome or other condition that would interfere with enteral absorption&#xD;
&#xD;
          -  Known untreated malignancies of the brain or spinal cord, or treated brain metastases&#xD;
             that are not radiographically stable for &gt;= 3 months&#xD;
&#xD;
          -  Active congestive heart failure or ventricular arrhythmia requiring medication&#xD;
&#xD;
          -  Active infection requiring IV antibiotics&#xD;
&#xD;
          -  Requirement for any daily supplemental oxygen&#xD;
&#xD;
          -  Uncontrolled hypomagnesemia&#xD;
&#xD;
          -  Hypercalcemia requiring continued use of bisphosphonate therapy&#xD;
&#xD;
          -  Clinically significant history of liver disease, including viral or other hepatitis,&#xD;
             current alcohol abuse, or cirrhosis&#xD;
&#xD;
          -  Uncontrolled ascites requiring frequent paracentesis&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Any other diseases, active or controlled pulmonary dysfunction, metabolic dysfunction,&#xD;
             physical examination finding, or clinical laboratory finding giving reasonable&#xD;
             suspicion of a disease or condition that contraindicates the use of an investigational&#xD;
             drug&#xD;
&#xD;
          -  Significant traumatic injury within 4 weeks of Day 1&#xD;
&#xD;
          -  Major surgical procedure within 4 weeks prior to initiation of GDC-0980&#xD;
&#xD;
          -  For all patients participating in Stage 2: Prior treatment with any PI3K inhibitor,&#xD;
             mTOR inhibitor or dual PI3K/mTOR inhibitor. For HNSCC patients, this restriction&#xD;
             applies only to any PI3K inhibitor, mTOR inhibitor, or dual PI3K/mTOR inhibitor used&#xD;
             in the palliative setting.&#xD;
&#xD;
          -  Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy,&#xD;
             oral contraceptives, or GnRH agonists or antagonists for prostate cancer),&#xD;
             immunotherapy, biologic therapy, radiation therapy (except palliative radiation to&#xD;
             bony metastases), or herbal therapy as cancer therapy within 3 weeks prior to&#xD;
             initiation of GDC-0980&#xD;
&#xD;
          -  Palliative radiation to bony metastases within 2 weeks prior to initiation of GDC-0980&#xD;
&#xD;
          -  Need for chronic corticosteroid therapy of &gt;= 10 mg of prednisone per day or an&#xD;
             equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant&#xD;
&#xD;
          -  Treatment with an investigational agent within 4 weeks prior to initiation of GDC-0980&#xD;
&#xD;
          -  Unresolved toxicity from prior therapy except for alopecia and Grade 1 peripheral&#xD;
             neuropathy&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  For patients participating in DCE-MRI assessments, any contraindication to MRI&#xD;
             examination&#xD;
&#xD;
          -  For patients with advanced solid tumors or NHL participating in the PPI-effect&#xD;
             assessment: Known hypersensitivity to rabeprazole, substituted benzimidazoles, or to&#xD;
             any component of the formulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mika Derynck, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2009</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>Tumors</keyword>
  <keyword>Carcinogenic Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

